Platelet‐Rich Plasma for Treating COVID‐19‐Related Anosmia, Hyposmia, and Parosmia: A Controlled Longitudinal Study
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.1149 ↗Kurz gefasst
Kontrollierte klinische Studie in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2025. Verfasst von Jerome R Lechien und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Polyclinic of Poitiers, Elsan, Poitiers, France. Hauptthemen laut MEDLINE: Anosmia, COVID-19, Olfaction Disorders, Platelet-Rich Plasma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Objective
To investigate the effectiveness of platelet‐rich plasma (PRP) injection into the olfactory clefts of coronavirus disease 2019 (COVID‐19) patients with persistent anosmia, hyposmia, and parosmia. Study Design Controlled study.
Setting
Multicenter study.
Methods
From March 2022 to July 2024, 514 COVID‐19 patients undergoing PRP injection and olfactory training versus olfactory training (controls) for a persistent olfactory dysfunction (OD) were consecutively recruited from two medical centers. Subjects were evaluated from pre‐ to 3 months post‐injection with the olfactory disorder questionnaire (ODQ) and the threshold, discrimination, and identification (TDI) test. Olfactory outcomes were compared between controls and patients considering the type of OD (anosmia, hyposmia, and parosmia).
Results
The PRP group was composed of 416 patients with anosmia (N = 111; 26.7%), hyposmia (N = 160; 38.5%), and parosmia (N = 145; 34.9%). The baseline ODQ of patients with parosmia was significantly higher than those of the other groups ( P = .001). The increase in TDI subscores and total score was significantly higher in all PRP subgroups compared to controls ( P = 0.001). The ODQ significantly reduced from pre‐ to post‐PRP injection in hyposmia and parosmia groups ( P = 0.001). Patients with parosmia showed a significantly greater reduction in ODQ scores compared to the control group. The 3‐month TDI score was negatively influenced by the age of patients ( r s = −0.263; P = 0.001) and the duration of OD ( r s = −0.213; P = .001).
Conclusion
Patients with parosmia experienced a stronger impact of OD on quality of life (QoL), and showed greater QoL improvement following PRP injections compared to other groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology, Polyclinic of Poitiers, Elsan, Poitiers, France.
- Department of Surgery, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.
- Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.
- Department of Otorhinolaryngology and Head and Neck Surgery, CHU Saint-Pierre, Brussels, Belgium.
- Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium.
Zitieren
APA
Lechien, J. R., & Saussez, S. (2025). Platelet‐Rich Plasma for Treating COVID‐19‐Related Anosmia, Hyposmia, and Parosmia: A Controlled Longitudinal Study. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1149
Vancouver
Lechien JR, Saussez S. Platelet‐Rich Plasma for Treating COVID‐19‐Related Anosmia, Hyposmia, and Parosmia: A Controlled Longitudinal Study. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1149
BibTeX
@article{Lechien2025,
author = {Lechien, Jerome R and Saussez, Sven},
title = {Platelet‐Rich Plasma for Treating COVID‐19‐Related Anosmia, Hyposmia, and Parosmia: A Controlled Longitudinal Study},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.1149}
}
EUVIMED